Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Unknown × Safety Issues × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 78 Carcinoma, Non-Small-Cell Lung 67 Breast Neoplasms 66 Recurrence 62 Carcinoma, Hepatocellular 54 Multiple Myeloma 52 Melanoma 51 Colorectal Neoplasms 51 Leukemia, Myeloid, Acute 48 Pancreatic Neoplasms 47 Advanced Solid Tumor 47 Neoplasm Metastasis 45 Advanced Solid Tumors 45 Lymphoma 44 Precursor Cell Lymphoblastic Leukemia-Lymphoma 40 Stomach Neoplasms 39 Solid Tumor 36 Ovarian Neoplasms 34 Lymphoma, B-Cell 34 Glioblastoma 34 Prostatic Neoplasms 30 Lung Neoplasms 30 Lymphoma, Non-Hodgkin 29 Leukemia 25 Uterine Cervical Neoplasms 23 Esophageal Neoplasms 23 Leukemia, Lymphocytic, Chronic, B-Cell 22 Burkitt Lymphoma 22 Head and Neck Neoplasms 21 Colonic Neoplasms 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05580172 2022-10-17

Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

ReHeva Biosciences,Inc.

Phase 1 Unknown

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon ⚡